← Back to all trials
Not Yet Recruiting
NCT07585097
A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
Conditions: Alagille Syndrome
Sex: All
Ages: 6 Months – N/A
Healthy volunteers: No
Enrollment: 30
Sponsor: Ipsen
Summary
This study will collect information from patients with ALGS who are using odevixibat in their daily lives. Odevixibat is a medication that helps patients with ALGS, a rare disease that affects the liver and causes itching.
The main aim of this study is to observe the long-term, everyday safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.
Eligibility Criteria
Inclusion Criteria:
* Diagnosed with ALGS.
* On (or starting) active odevixibat treatment.
* Aged 6 months or older at the time of consent.
Exclusion Criteria:
* Currently participating in a clinical trial with odevixibat.
* Currently participating in any interventional clinical trial for ALGS.
* Have any contraindication to odevixibat as per the locally approved label.
Source: ClinicalTrials.gov (NCT07585097). StuddyBuddy aggregates publicly available trial information.
